Analystreport

Blueprint Medicines Corp (NASDAQ: BPMC) had its price target raised by analysts at Piper Sandler from $77.00 to $81.00. They now have a "neutral" rating on the stock.

Blueprint Medicines Corporation  (BPMC) 
Last blueprint medicines corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: blueprintmedicines.com